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Black men suffer disproportionately from hypertension (HTN). Antihypertensive medication non-
adherence is a major contributor to poor blood pressure control, yet few studies consider how 
psychosocial functioning may impact Black men’s medication adherence. We examined direct and 
mediating pathways between depressive symptoms, psychosocial stressors, and substance use on 
antihypertensive medication non-adherence in 196 Black men enrolled in a clinical trial to 
improve HTN care and control. We found that greater depressive symptoms was associated with 
more medication non-adherence (β= 0.05, SE 0.01; p<.001). None of the psychosocial stressor 
variables were associated with antihypertensive medication non-adherence. Alcohol misuse was 
associated with more medication non-adherence (β=0.81, SE 0.26; p<.01), but it did not mediate 
the association between depressive symptoms and medication non-adherence. Clinicians should 
consider screening for depressive symptoms and alcohol misuse if patients are found to be non-
adherent and should treat or refer patients to appropriate resources to address those issues.
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Hypertension (HTN) accounts for half the excess CVD mortality observed in Blacks.1 Black 
men have a higher HTN prevalence, poorer blood pressure (BP) control, higher death rates 
due to HTN and more hypertension-related complications than non-Hispanic Whites 
(Whites) or Hispanics, 2, 3 even though the prevalence of BP control is improving.4 
Suboptimal antihypertensive medication adherence contributes to worse BP control and 
cardiovascular outcomes. Black men’s antihypertensive medication adherence is especially 
poor5, 6 and reasons for their non-adherence are not fully known.7 Few studies consider how 
psychosocial functioning may impact Black men’s medication adherence.
Findings from a five-year randomized clinical trial designed to improve HTN care and 
control among Black men with uncontrolled BP living in low socioeconomic status (SES) 
environments in Baltimore, Maryland, provide important background on the same study 
population that we report on in the current manuscript. In the parent study, researchers 
randomized men to a more intensive educational/behavioral/pharmacological intervention 
delivered by a team consisting of a nurse practitioner, community health worker, and a 
physician versus a less intensive education and referral intervention.8–10 Researchers found 
a trend towards improved anti-hypertensive medication adherence in both intervention 
groups; however, of concern was the fact that at five-year follow-up, 17% of the men in the 
study had died, with 36% of those deaths due to narcotic or alcohol withdrawal. Another 
analysis of the same study population found that depression was significantly associated 
with poor antihypertensive medication adherence and with alcohol use. 11 Although these 
researchers examined relationships between depressive symptoms, substance use and 
antihypertensive medication non-adherence and found that depression was associated with 
worse medication adherence in bivariate analyses, they did not report results from 
multivariate analyses nor did they test mediating pathways of this association.11
Many urban-residing Black men face psychosocial stressors (e.g., living in impoverished 
violent and crime-ridden neighborhoods, homelessness) 1213 that can precipitate and sustain 
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depression and adversely impact medication adherence.14, 15 These stressors and the coping 
behaviors (e.g., substance use) 16, 17 some men engage in to mitigate chronic stressors may 
adversely impact their medication adherence. This raised the question, which we wanted to 
explore further, of whether substance misuse in this population is a risk for worse 
medication adherence. To address limitations of previous studies, we examine direct and 
mediating pathways between depressive symptoms, psychosocial stressors, and substance 
use (both alcohol misuse and illicit drug use) on antihypertensive medication adherence in a 
sample of hypertensive Black men enrolled in a five-year clinical trial. Such research is 
critical to development of interventions to improve antihypertensive medication adherence 
in hypertensive Black men.
Methods
Study design and population
We conducted a repeated measures analysis on a sample drawn from a single-site five-year 
randomized clinical trial of 309 hypertensive Black men aged 21 and 54 years (at baseline: 
mean age 41 years; > 60% had a high school diploma or equivalent; 27% were employed 
either part- or full-time; 71% reported an annual income of <$10,000; 49% did not have a 
regular doctor for high blood pressure treatment; 64% reported a history of incarceration; 
45% had a positive urine screen for illicit drugs; mean systolic BP 146mmHg, and mean 
diastolic BP 99mmHg). Hill et al. provide additional information on the rationale for the 
parent study.8 The trial compared the effectiveness of a more intensive to a less intensive 
educational/behavioral/pharmacological intervention on HTN care and control.9, 10 Briefly, 
the more intensive intervention group received comprehensive HTN care, including 
education by a nurse practitioner (NP)/community health worker (CHW)/physician (MD) 
team. Visits with the NP occurred every one to three months at the Outpatient General 
Clinical Research Center (OPD-GCRC). The NP made therapeutic decisions including 
medication titration according to guideline-based protocol recommendations outlined in the 
Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure (JNC-VI).18 The CHW made at least 1 annual home visit 
to each participant and provided participants with need-based referrals to social services, job 
training, and housing. The MD was available for consultation with the NP at the time of NP 
visits. The study team addressed barriers to care and free antihypertensive medication was 
offered to participants; however, not all men received medication (e.g. men who had 
insurance coverage which paid for their medications). Men in the less intensive group 
received referral to community HTN care sources. Men in both groups were called and 
reminded of the importance of BP control every 6 months and were seen at the (OPD-
GCRC) annually for 5 years to collect data on study outcomes.
For the current analysis, the analytic sample included only clinical trial participants who 
attended annual study visits from months 24–60 and had their antihypertensive medication 
adherence assessed (Figure 1). Anti-hypertensive medication non-adherence was only 
assessed in men who reported being prescribed anti-hypertensive medication at each time 
period. We excluded data on anti-hypertensive medication non-adherence from baseline and 
month 12 visits because the psychosocial predictor variables of interest were not assessed at 
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those times. For this analysis, we combined the more and less intensive intervention groups, 
but consider intervention assignment as an effect modifier of the associations under study 
for some analyses.
Data collection
Staff interviewed participants to collect sociodemographic and behavioral risk factors. We 
measured each of the variables below at 24, 36, 48 and 60 months.
Outcome—We assessed antihypertensive medication adherence using the Hill-Bone 
Compliance Scale, Medication Taking subscale, which was developed in and validated for 
adult African American urban populations.19 This nine-item subscale uses a four-point 
Likert response format to assess frequency of the following BP medication taking behaviors: 
forgetting to take medication, deciding not to take medication, forgetting to get prescriptions 
filled, running out of medication, skipping medication, missing medication when feeling 
sick, missing medication when feeling better, taking someone else’s medication, and 
missing medication due to carelessness. The scale items were summed, resulting in a range 
of possible scores of 9–36, with higher scores indicating worse medication adherence. Given 
the inverse relationship between score and adherence, we hereafter refer to the outcome as 
antihypertensive medication “non-adherence.” Depressive symptoms. We used the Center 
for Epidemiologic Studies Depression (CES-D) scale to measure frequency of depressive 
symptoms.20 CES-D is a 20-item self-reported questionnaire which uses a four-point Likert 
response format to measure the following depressive symptoms within a one-week time 
frame: depressed mood, guilt or worthlessness, psychomotor retardation, loss of appetite, 
and sleep disturbances. CES-D is a widely used screening tool with established reliability 
and validity in Black populations.21 CES-D scores range from 0–60, with higher scores 
indicating increased frequency and number of depressive symptoms. A score of 16 or 
greater is indicative of depressive symptoms and has been validated with DSM-III criteria 
for clinical depression.
Psychosocial stressors—We developed a checklist for this study, which was adapted 
from the Holmes and Rahe social readjustment rating questionnaire22 and further modified 
based on field testing with members of the target group. For this checklist, participants’ 
reported the occurrence of five specific stressors: difficulty finding a place to live, being a 
victim of a violent act, being involved in a major/minor law violation, getting arrested or 
held in jail, and separating from a spouse or partner. Participants indicated which of these 
stressors they experienced during the six months preceding each follow-up visit (yes/no). 
We analyzed each stressor individually as a dichotomous variable and also examined the 
total number of stressors in aggregate.
Alcohol misuse—Assessed with the question: “Have you ever had an alcohol-related 
problem?” (yes/no).
Illicit drug use: Assessed using a standard urine screen for cocaine, opiates, barbiturates, 
cannabinoids and/or benzodiazepines by Quest Diagnostics which detected drug use 
occurred within the past 72 hours. The variable was dichotomized: 0=negative, 1=positive.
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Background variables—Guided by stress and coping23 and behavioral models, 24 we 
adjusted for the following variables hypothesized or shown to be associated with 
antihypertensive medication adherence.
Demographic characteristics: Assessed at each time period using items from the National 
Health Interview Survey.25 Marital status (married vs. not married), employment status 
(employed vs. unemployed), income (<$10,000 vs. ≥$10,000 annually) and who pays for 
medications (private insurance vs. public insurance vs. other- including self, family, or 
physician/nurse practitioner provided medication samples). Age and highest educational 
level reported at baseline were included in the statistical models.
Systolic and diastolic blood pressure: Measured by trained staff at the OPD-GCRC who 
were blinded to group assignment, using an appropriately sized cuff after the participant was 
seated for 5 minutes. Three BP measurements were obtained at 1-min intervals with a 
Hawksley random zero sphygmomanometer.26 The second and third BP measurements were 
averaged.
Tobacco use: Assessed by self-report of current smoking (1=current smoker, 0 
=nonsmoker).
Usual source of care: Assessed by asking participants if they had a regular provider for 
HTN care (yes/no).
Self-rated health: Assessed with the question, “Compared to other people your age, how 
would you rate your health?” Scored based on a four-point Likert response from 1=poor to 
4=excellent.
Intervention assignment: More vs. less intensive intervention groups.
Statistical analyses
Given the longitudinal nature of these data and the fact that there were drop-outs and losses 
to follow-up from the clinical trial participants from which our sample was drawn,8–10 we 
modeled whether the probability of missing outcome data was related to the following 
baseline variables: age, educational level, marital status, who pays for medications, 
employment, month, and intervention assignment. This analyses therefore controlled for 
biases that are not associated with the experimental manipulations that may affect the 
probability of missingness (e.g. whether due to drop out or death). We could not assess 
whether missingness was associated with any variables that were not obtained at baseline 
(e.g., depression, alcohol misuse). The probability of missing data was significantly related 
to month (p=.05) and marital status (.04). Therefore, we used a weighted estimating equation 
approach.27 In this approach, each person-visit was weighted inversely proportional to their 
probability of being observed. We then conducted repeated measures analyses with 
Weighted Generalized Estimating Equations using PROC GENMOD (SAS 9.2) examining 
psychosocial and behavioral predictors of antihypertensive medication non-adherence at 
each study period from 24 to 60 months. We built a series of models: the first modeled the 
relationships between the background variables and antihypertensive medication non-
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adherence. Subsequent models were then built with the addition of the following 
independent variables: depressive symptoms (model 2); psychosocial stressors (model 3); 
alcohol misuse (model 4); illicit drug use (model 5) and depressive symptoms, psychosocial 
stressors, alcohol misuse and illicit drug use (model 6). For independent variables that were 
found to be significantly associated with antihypertensive medication non-adherence, we 
examined whether those associations were moderated by intervention group. To this end, we 
conducted separate models testing the main and interaction effects on antihypertensive 
medication non-adherence between intervention group and the variable of interest.28
We conducted mediation analyses using hierarchical Generalized Estimating Equations 
(SAS PROC GENMOD) according to the mediational analytic framework described by 
Baron and Kenny to determine whether alcohol misuse mediates the association between 
depressive symptoms and medication non-adherence.28 In this approach, mediation exists 
when four conditions are met: (a) the predictor variable (i.e., depressive symptoms) is 
significantly related to the outcome variable (antihypertensive medication non-adherence), 
(b) the hypothesized mediator (i.e., alcohol misuse) is significantly related to the predictor 
variable, (c) the mediator is significantly related to the outcome, and (d) the relationship 
between the predictor and the outcome variables is significantly reduced when controlling 
for the mediator. We ran four regression models to estimate the relative effect size using 
unstandardized beta coefficients (β) needed to satisfy the four mediation criteria. We 
formally tested mediation effect using Sobel's mediation test.29
Results
Sample characteristics by study period
Sample sizes from months 24, 36, 48 and 60 were 196, 177, 166 and 151, respectively. 
Table 1 displays sample characteristics across study periods. Briefly, the mean highest 
educational level was about 11 years, about 20% were married, and the majority did not 
have insurance to cover their medications. About half of sample had good self-rated health; 
most were current smokers and approximately 40–50% had a positive urine screen for illicit 
drugs. Mean systolic and diastolic BP over time was about 141mmHg and 90mmHg. Over 
the study period, between 26–32% had depressive symptoms and 20–24% endorsed ever 
having had an alcohol-related problem.
Effects of time on antihypertensive medication non-adherence
The mean (SD) anti-hypertensive medication non-adherence scores at months 24, 36, 48 and 
60 were 11.1 (2.6), 10.6 (2.2), 11.7 (3.3), and 11.7 (2.9), respectively (see Figure 2). Given 
the possible range in medication non-adherence scores of 9–27, these scores indicate 
generally low medication non-adherence (i.e., good adherence). Compared with month 24, 
there was significantly less medication non-adherence at 36 months (β= −0.37, SE 0.16; 
p=0.02) and more non-adherence at 48 (β= 0.64, SE 0.22; p<0.01).
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Main effects of depressive symptoms, psychosocial stressors, alcohol misuse and illicit 
drug use on antihypertensive medication non-adherence
Of the background variables examined, only study period and intervention assignment were 
significantly related to antihypertensive medication non-adherence (Table 2, model 1). After 
adjustment for background variables, greater depressive symptoms was associated with 
more non-adherence (β= 0.05, SE 0.01; p<.001) (Table 2, model 2). None of the 
psychosocial stressor variables were associated with antihypertensive medication non-
adherence (Table 2, model 3), although there was a trend towards more non-adherence for 
men who were separated from a spouse or partner (β=0.85, SE 0.47; p=.07). Of note, there 
was a significant correlation between the number of psychosocial stressors and the total 
depressive symptom score (Pearson’s correlation coefficient= 0.23; p<.0001). Answering 
“yes” to ever having had an “alcohol-related problem” was associated with more medication 
non-adherence (β=0.81, SE 0.26; p<.01) than answering in the negative (Table 2, model 4). 
Illicit drug use was not significantly associated with worse medication non-adherence (Table 
2, model 5). When we include depressive symptom, psychosocial stressors, alcohol misuse, 
and illicit drug use in the same multivariate model to assess their independent associations 
with antihypertensive medication non-adherence (Table 2, model 6), depressive symptoms 
and alcohol misuse remain significantly associated with medication non-adherence.
Mediation and effect modification
Alcohol misuse did not mediate the association between depressive symptoms and 
antihypertensive medication non-adherence (β for condition “a” 0.06, p<.001; β for 
condition “d” 0.05, p<.001) (see Figure 3). Since neither illicit drug use nor psychosocial 
stressors were significantly associated with antihypertensive medication non-adherence, they 
did not meet criteria to be considered mediators of the association between depressive 
symptoms and medication non-adherence. There was evidence of effect modification by 
intervention group on the relationship between reporting having had an alcohol-related 
problem and antihypertensive medication non-adherence (β for interaction of intervention 
group x alcohol-related problem was 1.56, SE 0.55, p < .01 (see Figure 4). Among men in 
the less intensive group, those who reported having an alcohol-related problem were more 
non-adherent than those who did not report an alcohol-related problem (p < .01). In contrast, 
among men in the more intensive group, levels of antihypertensive medication non-
adherence did not differ as a function of their history of ever having an alcohol-related 
problem (Figure 4).
Discussion
We examined direct and mediating pathways between depressive symptoms, psychosocial 
stressors, and substance use (both alcohol misuse and illicit drug use) on antihypertensive 
medication non-adherence in a sample of hypertensive Black men enrolled in a clinical trial 
to improve HBP care and control. As hypothesized, we found that more depressive 
symptoms and alcohol misuse were associated with more antihypertensive medication non-
adherence over a three-year period. Alcohol misuse did not mediate the association between 
depressive symptoms and medication non-adherence. Contrary to our hypothesis, neither 
psychosocial stressors nor illicit drug use were significantly related to antihypertensive 
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medication non-adherence and therefore neither were mediators of the association between 
depressive symptoms and antihypertensive medication non-adherence. Overall, self-reported 
antihypertensive medication non-adherence scores varied over time.
Our finding that more depressive symptoms were associated with antihypertensive 
medication non-adherence is consistent with results from other studies.7, 30–36 While this 
finding is not novel, our study makes a unique contribution to the literature for several 
reasons. By using a prospective design we were able to document the consistency of this 
association over time. Further, our work highlights the chronicity of depressive symptoms 
and their effects on antihypertensive medication non-adherence in Black men specifically. 
This is important since other studies had an under-representation of Black men30, 31 or 
primarily targeted older adults.32
Our work supports findings from at least one other study which showed an association 
between alcohol misuse and antihypertensive medication non-adherence. 37 However, we 
did not find that alcohol misuse mediates the association between depressive symptoms and 
medication non-adherence. Kim et al. examined relationships between depressive 
symptoms, alcohol misuse, and antihypertensive medication non-adherence using the same 
study population as the current study, but they did not specifically examine alcohol misuse 
as a mediator. 25 Because we did not find any other studies which examined the 
relationships between depressive symptoms, alcohol misuse, and antihypertensive 
medication non-adherence, we cannot compare our findings with previous research. The 
mechanisms by which depressive symptoms affect medication adherence are unclear and 
likely complex. Some potential mechanisms include decreased self-care, decrements in 
memory and cognition, intentional self-harm and reduced self-efficacy. Future studies 
should assess other potential mediating factors in hypertensive Black men, to guide 
intervention development.
We found that the effect of alcohol misuse on antihypertensive medication non-adherence 
differs by intervention group. Among men in the less intensive group, those who reported 
ever having an alcohol-related problem were more non-adherent than those who did not 
report an alcohol-related problem. The interaction between alcohol misuse and intervention 
group might explain why we failed to find a significant mediation effect for alcohol misuse 
on the association between depressive symptoms and medication non-adherence. It is 
possible that alcohol misuse interacts with depressive symptoms to adversely affect 
antihypertensive medication adherence only among men with fewer resources and sources of 
positive support (i.e., men in the less intensive intervention group). Men in the more 
intensive group may have had other resources, even in the face of depressive symptoms, 
which helped to combat the potentially negative impact of alcohol misuse on their ability to 
adhere to their antihypertensive medications.
Our study has limitations. First, we used self-reported to assess antihypertensive medication 
non-adherence. Although some studies demonstrate moderate to strong concordance 
between self-reported medication adherence and pharmacy refill data,38, 39 other studies 
have shown that self-reported adherence does not correlate well with objective measures. 
Furthermore, there was little variability in antihypertensive medication non-adherence 
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scores. The lack of spread in this variable may make it difficult to identify significant 
correlations with other variables and may bias our findings towards the null. Future studies 
should assess antihypertensive medication non-adherence both subjectively and objectively. 
Second, since our analysis started at month 24, we did not examine associations between the 
predictor variables of interest and medication non-adherence at baseline. It is also possible 
that the intervention itself may have changed the level of some of our predictor variables 
(e.g., depressive symptoms, psychosocial stressors). Third, we did not use a validated 
questionnaire, such as the Alcohol Use Disorder Identification Test-Consumption (AUDIT-
C)40 to assess alcohol misuse. Our single item question, “have you ever had an alcohol-
related problem” does not differentiate individuals along the spectrum from “risky drinking” 
to “alcohol abuse and dependency.” Our question is a proxy for alcohol misuse which 
assesses any history of alcohol misuse rather than current alcohol misuse, which would be 
more appropriate and closely related to current medication non-adherence. Fourth, we used a 
non-validated measure of psychosocial stressors and limited response options to yes/no for 
each life event. While our approach may have reduced respondent burden, it may have 
resulted in measurement error and an inability to detect statistically significant associations. 
Finally, the external validity of our findings may be limited since our sample included Black 
men of relatively low socio-economic status who resided in Baltimore and were enrolled in 
a clinical trial.
Despite these limitations, our study has strengths. It was theoretically grounded and we 
empirically tested direct and mediating mechanisms for the known association between 
depressive symptoms and antihypertensive medication non-adherence. Further, we 
examined this clinically important issue in a sample of Black men – a highly 
underrepresented population in research. We screened for the presence of depressive 
symptoms using a validated instrument. Finally, we used a prospective design which 
allowed us to examine antihypertensive medication non-adherence and psychosocial factors 
over time.
Our study has important implications for clinical practice and research. The findings extend 
our understanding of psychosocial factors that might limit the effectiveness of HTN 
treatment by interfering with medication adherence in a high-risk population of Black men. 
Given the strong and persistent association of depressive symptoms and alcohol misuse with 
antihypertensive medication non-adherence, clinicians should consider routine and ongoing 
screening for depressive symptoms and alcohol misuse in hypertensive Black men who are 
non-adherent with their antihypertensive medications. Clinicians and researchers interested 
in improving HTN control and cardiovascular outcomes through better medication 
adherence should continue to investigate and intervene upon the myriad psychosocial factors 
operant in the lives of Black men which adversely impacts their ability to adhere to therapy. 
Future research should examine whether identifying and treating depression and alcohol 
misuse disorders in Black men improves medication adherence and ultimately BP control 
and cardiovascular outcomes.
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We presented earlier versions of this manuscript as presentations at the 48th American Heart Association 
Cardiovascular Disease Epidemiology and Prevention Annual Conference in Colorado Springs, Colorado in 2008 
and at the Society of General Internal Medicine National Meeting in Pittsburgh, Pennsylvania in 2008.
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Study participant attendance and outcome assessment by study period. Study follow-up rates 
account for the numbers of men who were: decreased (n= 18,34,44,53), incarcerated 
(n=14,21,21,24), had moved out-of-state (n=6,5,6,9) or were in a long-term care facility 
(n=1,2,2,2) at 24, 36, 48 and 60 months, respectively.
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Mean adherence score using Hill-Bone Compliance Scale, Medication Taking subscale over 
study period *Lower scores indicate better medication adherence
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Mediational model showing both the direct and the mediated pathways by which depressive 
symptoms influence antihypertensive medication non-adherence.
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Effect modification by intervention group of association between alcohol misuse and 
antihypertensive medication non-adherence
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Table 1
Sample Characteristics By Study Period
Characteristic
Sample mean ± SD or N (%)
Month 24 (N=196) Month 36 (N=177) Month 48 (N=166) Month 60 (N=151)
Background/control variables
Age (yrs) 41.7 ± 5.6 42.3 ± 5.4 42.0 ± 5.6 41.9± 5.6
Education (yrs) 11.4 ± 2.0 11.4± 2.2 11.6± 2.2 11.6± 2.0
Currently married (vs. not married) 37 (19) 36 (20) 35 (21) 34 (23)
Systolic BP, mmHg 142.7±19.2 140.9±21.3 140.1±21.0 141.8±23.5
Diastolic BP, mmHg 87.9 ± 12.5 89.8±14.1 91.0±13.8 93.4±16.0
Who pays for medications
 Private 39 (20) 36 (20) 30 (18) 27 (18)
 Public 43 (22) 37 (21) 27 (16) 21 (14)
 Other (including self, family, or samples 
provided by MD or NP)
113 (58) 103 (59) 108 (65) 101 (68)
Self-rated health
 Poor 12 (6) 7 (4) 8 (5) 7 (5)
 Fair 51 (6) 44 (26) 41 (25) 36 (24)
 Good 91 (48) 86 (50) 78 (48) 71 (48)
 Excellent 37 (19) 35 (20) 34 (21) 33 (22)
Current smoker (vs. non-smoker) 138 (73) 118 (67) 109 (66) 95 (63)
Urine screen positive for Illicit drugs 90 (49) 75 (43) 67 (41) 56 (39)
Depressive symptoms
CES-D score 10.9 ± 8.1 11.4± 9.4 10.9± 9.5 12.7± 11.5
CES-D ≥ 16 54 (28) 46 (26) 43 (26) 48 (32)
Psychosocial stressors (in past 6 months)
Victim of violent act 15 (8) 0 (0) 10 (6) 8 (5)
Major or minor law violation 13 (7) 6 (3) 12 (7) 10 (7)
Arrested or held in jail 16 (8) 6 (3) 14 (8) 9 (6)
Difficulty finding a place to live 14 (7) 6 (3) 20 (12) 14 (9)
Separated spouse or partner 13 (5) 12 (5) 31 (14) 20 (10)
Employed (vs. unemployed) 71 (36) 68 (38) 61 (37) 64 (42)
Alcohol Misuse
Ever had an alcohol-related problem (vs. not) 39 (20) 37 (21) 40 (24) 36 (24)
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Table 2
Linear association between Independent Variables and Antihypertensive Medication Non- adherence
Beta coefficient (β) SE P value
Model 1: Background characteristics*
Month 24 Ref Ref Ref
Month 36 −0.28 0.16 0.07
Month 48 0.69 0.23 <0.01
Month 60 0.29 0.21 0.15
Less intensive intervention group Ref Ref Ref
More intensive intervention group −0.73 0.32 0.02
Model 2: Depressive symptoms†
Depression score 0.05 0.01 <0.001
Model 3: Psychosocial stressors†
Victim of a violent act within past 6 months −0.50 0.39 0.21
Major or minor law violation within past 6 months 0.17 0.41 0.69
Been arrested or held in jail within past 6 months 0.22 0.43 0.60
Difficulty finding a place to live within past 6 months 0.31 0.40 0.43
Separated from spouse or partner within past 6 months 0.85 0.47 0.07
Model 4: Alcohol Misuse†
Answered “yes” to ever having had an “alcohol-related problem” 0.81 0.26 <0.01
Model 5: Negative urine screen for illicit drugs 0.04 0.20 0.84
Model 6: Depressive symptoms, Psychosocial stressors Alcohol misuse, and Illicit drug use†
Depression score 0.04 0.01 <0.001
Victim of a violent act within past 6 months −0.71 0.41 0.09
Major or minor law violation within past 6 months −0.09 0.40 0.82
Been arrested or held in jail within past 6 months 0.21 0.43 0.62
Difficulty finding a place to live within past 6 months 0.22 0.41 0.58
Separated from spouse or partner within past 6 months 0.85 0.45 0.06
Alcohol Misuse 0.70 0.27 0.01
Negative urine screen for illicit drugs 0.10 0.20 0.60
*
None of the following other background characteristics that we adjusted for were significantly associated with hypertension medication non-
adherence at p<0.10 level: age, education, who pays for medications, marital status, systolic BP, diastolic BP, current smoking, and self-rated 
health
†
Adjusted for background characteristics
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